Danaher Corporation (DHR) showed mixed performance in the headlines. The company’s stock performance went through a rough patch, with shares hitting a
52-week low at $225.36 and underperforming the market. DHR also reported an
8.6% plunge, which has investors concerned.
Despite falling short on Q4 earnings by
5.5%, DHR's
revenue surged to $6.5B, with strong growth projected for 2025, and Life Sciences sales increased. Q4 sales also beat estimates and investors seem satisfied with DHR's prospects.
Hedge funds and notable investors express confidence in the company. Additional attention comes from Dan Loeb, with DHR among his top stock picks. Despite these, DHR also faced criticism and disappointment from financial guru Jim Cramer.
Several investment firms have adjusted DHR's stock prices down. Yet, it is worthy to note that some firms maintained a
Buy rating despite the changes.
In terms of transactions, many entities have sold their DHR shares, yet a significant volume of call options has been reported. Equally, several groups and banks made substantial investments acquiring new shares.
Danaher Corporation DHR News Analytics from Fri, 27 Sep 2024 07:00:00 GMT to Sat, 01 Feb 2025 21:13:58 GMT -
Rating -2
- Innovation 5
- Information 7
- Rumor -5
